Evidence map›Paper›PMID 34031819›Full record

ArticlePharmaceutical medicine2021

The Utility of Patient Engagement in Drug Research and Development.

Avani Patel, Daniel Fiebig, Juliette Muszka

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Avani PatelSanofi, 55 Corporate Drive, Bridgewater, NJ, 08807, USA. avpatelm@gmail.com.ORCID 0000-0001-9305-411X
Daniel FiebigSanofi, 55 Corporate Drive, Bridgewater, NJ, 08807, USA.
Juliette MuszkaSanofi, 55 Corporate Drive, Bridgewater, NJ, 08807, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug development of transformative medicine has compounding complexity as researchers seek to address the varying needs of patients, providers, payers, and policymakers. Patient engagement frameworks and guidance are under development with health authorities that will further guide patient engagement in drug research. Patient insights have been captured in registries, online health networks, and other forums to inform evidence on disease progression and identify gaps in care. Patient representation and disease awareness have improved in partnership with patient advocacy groups that have led to patient-informed drug development. One effort to incorporate the patient voice into early research and development (R&D) is the Patient Insights Database (PID). Currently comprising 102 indications, the PID was developed to uncover trends in mixed methods research data, including direct patient interviews and evidence-based medicine. The database is used to understand patient symptomology, diagnosis, treatment, health-related quality of life (HR-QoL), economic burden, and hope for new therapies, based on patient interviews, patient testimonials, real-world evidence studies, and HR-QoL research. A deep understanding of the patient experience informs internal R&D decisions to bring forth healthcare solutions that address patient needs.

Indexed as

Pharmaceutical PreparationsQuality of LifeHumansPatient ParticipationResearchPharmaceutical Preparations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.